Jackie Collins

An olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.

A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.

In CheckMate040, single-agent nivolumab achieved durable responses in patients with advanced hepatocelluar carcinoma.

Patients with previously treated HER2-positive metastatic breast cancer experienced a clinically meaningful and statistically significant improvement in progression-free survival with fam-trastuzumab deruxtecan-nxki vs standard of care trastuzumab emtansine in the DESTINY-Breast03 trial.

Roughly 50% of patients with clear cell renal cell carcinoma responded to the combination of nivolumab plus ipilimumab in a Japanese study, and varied responses occurred in those with nonclear cell histology.

Real-world evidence shows robust adherence rates and prostate-specific antigen response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

High adherence rates and favorable prostate-specific antigen response to apalutamide where seen in Patients with nonmetastatic castration-resistant prostate cancer.